

# Florence S H Wong

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2042540/publications.pdf>

Version: 2024-02-01

161  
papers

13,337  
citations

28274

55  
h-index

23533

111  
g-index

168  
all docs

168  
docs citations

168  
times ranked

7036  
citing authors

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 1  | The management of ascites in cirrhosis: Report on the consensus conference of the International Ascites Club. <i>Hepatology</i> , 2003, 38, 258-266.   | 7.3  | 744       |
| 2  | Diagnosis and management of acute kidney injury in patients with cirrhosis: Revised consensus recommendations of the International Club of Ascites. <i>Journal of Hepatology</i> , 2015, 62, 968-974.                                      | 3.7  | 571       |
| 3  | Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. <i>Postgraduate Medical Journal</i> , 2008, 84, 662-670.   | 1.8  | 504       |
| 4  | Transjugular Intrahepatic Portosystemic Shunt for Refractory Ascites: A Meta-analysis of Individual Patient Data. <i>Gastroenterology</i> , 2007, 133, 825-834.  | 1.3  | 494       |
| 5  | Survival in infection-related acute-on-chronic liver failure is defined by extrahepatic organ failures. <i>Hepatology</i> , 2014, 60, 250-256.   | 7.3  | 456       |
| 6  | Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. <i>Hepatology</i> , 2000, 31, 207-210.  | 7.3  | 435       |
| 7  | The North American Study for the Treatment of Refractory Ascites. <i>Gastroenterology</i> , 2003, 124, 634-641.  | 1.3  | 424       |
| 8  | Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. <i>Gut</i> , 2015, 64, 531-537.  | 12.1 | 405       |
| 9  | Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. <i>Hepatology</i> , 2004, 40, 55-64.   | 7.3  | 369       |
| 10 | Hepatic and portal vein thrombosis in cirrhosis: Possible role in development of parenchymal extinction and portal hypertension. <i>Hepatology</i> , 1995, 21, 1238-1247.  | 7.3  | 366       |
| 11 | Working Party proposal for a revised classification system of renal dysfunction in patients with cirrhosis. <i>Gut</i> , 2011, 60, 702-709.  | 12.1 | 359       |
| 12 | Second infections independently increase mortality in hospitalized patients With cirrhosis: the north american consortium for the study of end-stage liver disease (NACSELD) experience. <i>Hepatology</i> , 2012, 56, 2328-2335.          | 7.3  | 357       |
| 13 | Hyponatremia in cirrhosis: Results of a patient population survey. <i>Hepatology</i> , 2006, 44, 1535-1542.  | 7.3  | 349       |
| 14 | Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. <i>Hepatology</i> , 2021, 74, 1014-1048. | 7.3  | 311       |
| 15 | Epidemiology and Effects of Bacterial Infections in Patients With Cirrhosis Worldwide. <i>Gastroenterology</i> , 2019, 156, 1368-1380.e10.   | 1.3  | 296       |
| 16 | A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: A multicenter, randomized, placebo-controlled trial. <i>Hepatology</i> , 2003, 37, 182-191.                                 | 7.3  | 269       |
| 17 | Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome. <i>New England Journal of Medicine</i> , 2021, 384, 818-828.   | 27.0 | 235       |
| 18 | Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1. <i>Gastroenterology</i> , 2016, 150, 1579-1589.e2.                                  | 1.3  | 225       |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 19 | Transjugular Intrahepatic Portosystemic Stent Shunt: Effects on Hemodynamics and Sodium Homeostasis in Cirrhosis and Refractory Ascites. <i>Annals of Internal Medicine</i> , 1995, 122, 816.             | 3.9  | 223       |
| 20 | New Consensus Definition of Acute Kidney Injury Accurately Predicts 30-Day Mortality in Patients With Cirrhosis and Infection. <i>Gastroenterology</i> , 2013, 145, 1280-1288.e1.                         | 1.3  | 221       |
| 21 | Acute kidney injury in decompensated cirrhosis. <i>Gut</i> , 2013, 62, 131-137.   | 12.1 | 205       |
| 22 | NACSELD acute-on-chronic liver failure (NACSELD-aCLF) score predicts 30-day survival in hospitalized patients with cirrhosis. <i>Hepatology</i> , 2018, 67, 2367-2374.                                    | 7.3  | 197       |
| 23 | The 3-month readmission rate remains unacceptably high in a large North American cohort of patients with cirrhosis. <i>Hepatology</i> , 2016, 64, 200-208.  | 7.3  | 189       |
| 24 | Effects of sivataptan, a selective vasopressin V <sub>2</sub> receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: A randomized trial. <i>Hepatology</i> , 2008, 48, 204-213. | 7.3  | 183       |
| 25 | Comparison of mortality risk in patients with cirrhosis and COVID-19 compared with patients with cirrhosis alone and COVID-19 alone: multicentre matched cohort. <i>Gut</i> , 2021, 70, 531-536.          | 12.1 | 178       |
| 26 | Cirrhotic cardiomyopathy. <i>Hepatology International</i> , 2009, 3, 294-304.   | 4.2  | 172       |
| 27 | Hepatorenal syndrome. <i>Nature Reviews Disease Primers</i> , 2018, 4, 23.  | 30.5 | 172       |
| 28 | Refractory ascites: pathogenesis, definition and therapy of a severe complication in patients with cirrhosis. <i>Liver International</i> , 2010, 30, 937-947.   | 3.9  | 161       |
| 29 | The Use of E/A Ratio as a Predictor of Outcome in Cirrhotic Patients Treated With Transjugular Intrahepatic Portosystemic Shunt. <i>American Journal of Gastroenterology</i> , 2009, 104, 2458-2466.      | 0.4  | 160       |
| 30 | Hepatorenal syndrome: the 8th international consensus conference of the Acute Dialysis Quality Initiative (ADQI) group. <i>Critical Care</i> , 2012, 16, R23.   | 5.8  | 145       |
| 31 | The hyperdynamic circulation in cirrhosis. , 2001, 89, 221-231.   |      | 127       |
| 32 | Outcomes of patients with cirrhosis and hepatorenal syndrome type 1 treated with liver transplantation. <i>Liver Transplantation</i> , 2015, 21, 300-307.   | 2.4  | 122       |
| 33 | Satavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum of ascites severity. <i>Gut</i> , 2012, 61, 108-116.   | 12.1 | 121       |
| 34 | Role of cardiac structural and functional abnormalities in the pathogenesis of hyperdynamic circulation and renal sodium retention in cirrhosis. <i>Clinical Science</i> , 1999, 97, 259-267.             | 4.3  | 109       |
| 35 | Long-term Use of Antibiotics and Proton Pump Inhibitors Predict Development of Infections in Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 753-759.e2.             | 4.4  | 105       |
| 36 | Recent advances in our understanding of hepatorenal syndrome. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2012, 9, 382-391.   | 17.8 | 91        |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 37 | Effects of ascites resolution after successful TIPS on nutrition in cirrhotic patients with refractory ascites. <i>American Journal of Gastroenterology</i> , 2001, 96, 2442-2447.  | 0.4  | 90        |
| 38 | Acute-on-Chronic Liver Failure Clinical Guidelines. <i>American Journal of Gastroenterology</i> , 2022, 117, 225-252.   | 0.4  | 90        |
| 39 | Association Between Intestinal Microbiota Collected at Hospital Admission and Outcomes of Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 756-765.e3.  | 4.4  | 89        |
| 40 | Prediction of Fungal Infection Development and Their Impact on Survival Using the NACSELD Cohort. <i>American Journal of Gastroenterology</i> , 2018, 113, 556-563.   | 0.4  | 87        |
| 41 | Acute-on-Chronic Liver Failure: Getting Ready for Prime Time?. <i>Hepatology</i> , 2018, 68, 1621-1632.   | 7.3  | 86        |
| 42 | Central blood volume in cirrhosis: Measurement with radionuclide angiography. <i>Hepatology</i> , 1994, 19, 312-321.  | 7.3  | 83        |
| 43 | Molecular adsorbent recirculating system is ineffective in the management of type 1 hepatorenal syndrome in patients with cirrhosis with ascites who have failed vasoconstrictor treatment. <i>Gut</i> , 2010, 59, 381-386.           | 12.1 | 83        |
| 44 | Bacterial infections in end-stage liver disease: current challenges and future directions. <i>Gut</i> , 2012, 61, 1219-1225.  | 12.1 | 81        |
| 45 | New challenge of hepatorenal syndrome: Prevention and treatment. <i>Hepatology</i> , 2001, 34, 1242-1251.   | 7.3  | 78        |
| 46 | Effects of a selective vasopressin V2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosis. <i>Journal of Hepatology</i> , 2010, 53, 283-290.   | 3.7  | 78        |
| 47 | Clinical features and evolution of bacterial infection-related acute-on-chronic liver failure. <i>Journal of Hepatology</i> , 2021, 74, 330-339.  | 3.7  | 76        |
| 48 | Pattern of sodium handling and its consequences in patients with preascitic cirrhosis. <i>Gastroenterology</i> , 1995, 108, 1820-1827.  | 1.3  | 68        |
| 49 | Brain natriuretic peptide: is it a predictor of cardiomyopathy in cirrhosis?. <i>Clinical Science</i> , 2001, 101, 621-628.   | 4.3  | 68        |
| 50 | Drug Insight: the role of albumin in the management of chronic liver disease. <i>Nature Reviews Gastroenterology &amp; Hepatology</i> , 2007, 4, 43-51.   | 1.7  | 68        |
| 51 | Management of ascites in cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 11-20.  | 2.8  | 68        |
| 52 | Long-term clinical outcome of patients with cirrhosis and refractory ascites treated with transjugular intrahepatic portosystemic shunt insertion. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 389-395. | 2.8  | 66        |
| 53 | Acute kidney injury in liver cirrhosis: new definition and application. <i>Clinical and Molecular Hepatology</i> , 2016, 22, 415-422.   | 8.9  | 65        |
| 54 | Serum Levels of Metabolites Produced by Intestinal Microbes and Lipid Moieties Independently Associated With Acute-on-Chronic Liver Failure and Death in Patients With Cirrhosis. <i>Gastroenterology</i> , 2020, 159, 1715-1730.e12. | 1.3  | 65        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 55 | Long-term renal sodium handling in patients with cirrhosis treated with transjugular intrahepatic portosystemic shunts for refractory ascites <sup>22</sup> Part of this work was performed while holding a Fellowship in Hepatology from Schering Canada.. American Journal of Medicine, 1999, 106, 315-322. | 1.5 | 63        |
| 56 | Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis. Clinical Gastroenterology and Hepatology, 2016, 14, 1821-1830.e6.  | 4.4 | 61        |
| 57 | High risk of delisting or death in liver transplant candidates following infections: Results from the North American consortium for the study of end-stage liver disease. Liver Transplantation, 2015, 21, 881-888.   | 2.4 | 59        |
| 58 | Glomerular hyperfiltration in patients with well-compensated alcoholic cirrhosis. Gastroenterology, 1993, 104, 884-889.   | 1.3 | 55        |
| 59 | Impact of Chronic Kidney Disease on Outcomes in Cirrhosis. Liver Transplantation, 2019, 25, 870-880.  | 2.4 | 55        |
| 60 | Terlipressin Improves Renal Function and Reverses Hepatorenal Syndrome in Patients With Systemic Inflammatory Response Syndrome. Clinical Gastroenterology and Hepatology, 2017, 15, 266-272.e1.  | 4.4 | 53        |
| 61 | Outcomes After Listing for Liver Transplant in Patients With Acute-on-Chronic Liver Failure: The Multicenter North American Consortium for the Study of End-stage Liver Disease Experience. Liver Transplantation, 2019, 25, 571-579.   | 2.4 | 53        |
| 62 | Renal response to a saline load in well-compensated alcoholic cirrhosis. Hepatology, 1994, 20, 873-881.   | 7.3 | 51        |
| 63 | Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus genotype 5 or 6 infection (ENDURANCE-5,6): an open-label, multicentre, phase 3b trial. The Lancet Gastroenterology and Hepatology, 2019, 4, 45-51.   | 8.1 | 48        |
| 64 | Refractory Ascites in Liver Cirrhosis. American Journal of Gastroenterology, 2019, 114, 40-47.  | 0.4 | 46        |
| 65 | The Impact of Albumin Use on Resolution of Hyponatremia in Hospitalized Patients With Cirrhosis. American Journal of Gastroenterology, 2018, 113, 1339.   | 0.4 | 44        |
| 66 | Beta-blockers in cirrhosis: Friend and foe?. Hepatology, 2010, 52, 811-813.   | 7.3 | 43        |
| 67 | The renal sympathetic and renin-angiotensin response to lower body negative pressure in well-compensated cirrhosis. Gastroenterology, 1998, 115, 397-405.   | 1.3 | 42        |
| 68 | The mechanism of improved sodium homeostasis of low-dose losartan in preascitic cirrhosis. Hepatology, 2002, 35, 1449-1458.   | 7.3 | 42        |
| 69 | Pathways of hepatic and renal damage through non-classical activation of the renin-angiotensin system in chronic liver disease. Liver International, 2020, 40, 18-31.   | 3.9 | 42        |
| 70 | Model for End-stage Liver Disease Lactate and Prediction of Inpatient Mortality in Patients With Chronic Liver Disease. Hepatology, 2020, 72, 1747-1757.  | 7.3 | 42        |
| 71 | Lack of renal improvement with nonselective endothelin antagonism with tezosentan in type 2 hepatorenal syndrome. Hepatology, 2007, 47, 160-168.  | 7.3 | 41        |
| 72 | Nosocomial Infections Are Frequent and Negatively Impact Outcomes in Hospitalized Patients With Cirrhosis. American Journal of Gastroenterology, 2019, 114, 1091-1100.  | 0.4 | 41        |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 73 | The use of TIPS in chronic liver disease. <i>Annals of Hepatology</i> , 2006, 5, 5-15.  | 1.5  | 40        |
| 74 | Role of cardiac structural and functional abnormalities in the pathogenesis of hyperdynamic circulation and renal sodium retention in cirrhosis. <i>Clinical Science</i> , 1999, 97, 259.   | 4.3  | 38        |
| 75 | Transjugular intrahepatic portosystemic shunt for refractory ascites: Tipping the sodium balance. <i>Hepatology</i> , 1995, 22, 358-364.  | 7.3  | 36        |
| 76 | The evolving concept of acute kidney injury in patients with cirrhosis. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2015, 12, 711-719.  | 17.8 | 35        |
| 77 | New diagnostic criteria and management of acute kidney injury. <i>Journal of Hepatology</i> , 2017, 66, 860-861.  | 3.7  | 35        |
| 78 | Admission Urinary and Serum Metabolites Predict Renal Outcomes in Hospitalized Patients With Cirrhosis. <i>Hepatology</i> , 2021, 74, 2699-2713.  | 7.3  | 27        |
| 79 | Satavaptan treatment for ascites in patients with cirrhosis: a meta-analysis of effect on hepatic encephalopathy development. <i>Metabolic Brain Disease</i> , 2013, 28, 301-305.   | 2.9  | 26        |
| 80 | A cut-off serum creatinine value of 1.5 mg/dl for AKI â€œ To be or not to be. <i>Journal of Hepatology</i> , 2015, 62, 741-743.   | 3.7  | 25        |
| 81 | An update on the pathogenesis and clinical management of cirrhosis with refractory ascites. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 293-305.  | 3.0  | 25        |
| 82 | Cirrhosis Is Associated With High Mortality and Readmissions Over 90 Days Regardless of COVIDâ€™19: A Multicenter Cohort. <i>Liver Transplantation</i> , 2021, 27, 1343-1347.   | 2.4  | 25        |
| 83 | Health Care Utilization and Costs for Patients With End-Stage Liver Disease Are Significantly Higher at the End of Life Compared to Those of Other Decedents. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2339-2346.e1. | 4.4  | 24        |
| 84 | Brain natriuretic peptide: is it a predictor of cardiomyopathy in cirrhosis?. <i>Clinical Science</i> , 2001, 101, 621.   | 4.3  | 23        |
| 85 | Pretransplant Type 2 Hepatorenal Syndrome Is Associated With Persistently Impaired Renal Function After Liver Transplantation. <i>Transplantation</i> , 2015, 99, 1441-1446.  | 1.0  | 23        |
| 86 | Albumin May Prevent the Morbidity of Paracentesis-Induced Circulatory Dysfunction in Cirrhosis and Refractory Ascites: A Pilot Study. <i>Digestive Diseases and Sciences</i> , 2016, 61, 3084-3092.                                     | 2.3  | 23        |
| 87 | Clinical Features of Patients With Philadelphia-Negative Myeloproliferative Neoplasms Complicated by Portal Hypertension. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, e1-e5.   | 0.4  | 22        |
| 88 | Reduction in acute kidney injury stage predicts survival in patients with type-1 hepatorenal syndrome. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1554-1561.  | 0.7  | 22        |
| 89 | Ascites and Hepatorenal Syndrome. <i>Clinics in Liver Disease</i> , 2019, 23, 659-682.  | 2.1  | 20        |
| 90 | Management of hepatorenal syndrome in liver cirrhosis: a recent update. <i>Therapeutic Advances in Gastroenterology</i> , 2022, 15, 175628482211026.  | 3.2  | 20        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 91  | Refractory ascites in cirrhosis: Roles of volume expansion and plasma atrial natriuretic factor level elevation. <i>Hepatology</i> , 1993, 18, 519-528.                                   | 7.3 | 19        |
| 92  | Gender-Specific Differences in Baseline, Peak, and Delta Serum Creatinine: The NACSELD Experience. <i>Digestive Diseases and Sciences</i> , 2017, 62, 768-776.                            | 2.3 | 19        |
| 93  | Improvement in Quality of Life and Decrease in Large-Volume Paracentesis Requirements With the Automated Low-Flow Ascites Pump. <i>Liver Transplantation</i> , 2020, 26, 651-661.         | 2.4 | 19        |
| 94  | Variations in albumin use in patients with cirrhosis: An AASLD members survey. <i>Hepatology</i> , 2015, 62, 1923-1924.   | 7.3 | 18        |
| 95  | REVIEW: The controversy over the pathophysiology of ascites formation in cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1997, 12, 437-444.                    | 2.8 | 17        |
| 96  | Outcomes in Patients With Cirrhosis on Primary Compared to Secondary Prophylaxis for Spontaneous Bacterial Peritonitis. <i>American Journal of Gastroenterology</i> , 2019, 114, 599-606. | 0.4 | 17        |
| 97  | Underutilization of Hospice in Inpatients with Cirrhosis: The NACSELD Experience. <i>Digestive Diseases and Sciences</i> , 2020, 65, 2571-2579.   | 2.3 | 17        |
| 98  | Low Predictability of Readmissions and Death Using Machine Learning in Cirrhosis. <i>American Journal of Gastroenterology</i> , 2021, 116, 336-346.                                       | 0.4 | 17        |
| 99  | Liver and kidney diseases. <i>Clinics in Liver Disease</i> , 2002, 6, 981-1011.   | 2.1 | 16        |
| 100 | Increased Risk of ACLF and Inpatient Mortality in Hospitalized Patients with Cirrhosis and Hepatic Hydrothorax. <i>Digestive Diseases and Sciences</i> , 2021, 66, 3612-3618.             | 2.3 | 15        |
| 101 | The use of TIPS in chronic liver disease. <i>Annals of Hepatology</i> , 2006, 5, 5-15.  | 1.5 | 15        |
| 102 | Unprecipitated acute kidney injury is uncommon among stable patients with cirrhosis and ascites. <i>Liver International</i> , 2018, 38, 1785-1792.  | 3.9 | 14        |
| 103 | Progression of Stage 2 and 3 Acute Kidney Injury in Patients With Decompensated Cirrhosis and Ascites. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1661-1669.e2.          | 4.4 | 14        |
| 104 | Acute kidney injury: prediction, prognostication and optimisation for liver transplant. <i>Hepatology International</i> , 2020, 14, 167-179.  | 4.2 | 14        |
| 105 | COVID-19 and Liver Cirrhosis: Focus on the Nonclassical Renin-Angiotensin System and Implications for Therapy. <i>Hepatology</i> , 2021, 74, 1074-1080.                                   | 7.3 | 14        |
| 106 | Volume expanders for spontaneous bacterial peritonitis: Are we comparing oranges with oranges?. <i>Hepatology</i> , 2005, 42, 533-535.  | 7.3 | 13        |
| 107 | Renal Diseases and the Liver. <i>Clinics in Liver Disease</i> , 2011, 15, 39-53.  | 2.1 | 13        |
| 108 | Renal Dysfunction After Liver Transplantation: Effect of Donor Type. <i>Liver Transplantation</i> , 2020, 26, 799-810.  | 2.4 | 13        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 109 | Daclatasvir and Sofosbuvir with Ribavirin for 24 Weeks in Chronic Hepatitis C Genotype-3-Infected Patients with Cirrhosis: A Phase III Study (ALLY-3C). <i>Antiviral Therapy</i> , 2019, 24, 35-44.                                      | 1.0 | 12        |
| 110 | Treatment of Oesophageal Varices in Liver Cirrhosis. <i>Digestion</i> , 2019, 99, 261-266.   | 2.3 | 12        |
| 111 | Central blood volume in cirrhosis: Measurement with radionuclide angiography. <i>Hepatology</i> , 1994, 19, 312-321.   | 7.3 | 12        |
| 112 | Hepatorenal syndrome: Current management. <i>Current Gastroenterology Reports</i> , 2008, 10, 22-29.   | 2.5 | 11        |
| 113 | Clinical Consequences of Infection in Cirrhosis: Organ Failures and Acute to Chronic Liver Failure. <i>Clinical Liver Disease</i> , 2019, 14, 92-97.   | 2.1 | 11        |
| 114 | The Prediction of In-Hospital Mortality in Decompensated Cirrhosis with Acute to Chronic Liver Failure. <i>Liver Transplantation</i> , 2022, 28, 560-570.  | 2.4 | 11        |
| 115 | Diagnosing and treating renal disease in cirrhotic patients. <i>Minerva Gastroenterologica E Dietologica</i> , 2016, 62, 253-66.   | 2.2 | 11        |
| 116 | Kidney damage biomarkers: Novel tools for the diagnostic assessment of acute kidney injury in cirrhosis. <i>Hepatology</i> , 2014, 60, 455-457.  | 7.3 | 10        |
| 117 | THE PATHOPHYSIOLOGIC BASIS FOR THE TREATMENT OF CIRRHOTIC ASCITES. <i>Clinics in Liver Disease</i> , 2001, 5, 819-832.   | 2.1 | 9         |
| 118 | Medical management of ascites. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 1269-1283.   | 1.8 | 9         |
| 119 | Effects of Sodium Status on the Venous Response to Noradrenaline Infusion in Pre-Ascitic Cirrhosis. <i>Clinical Science</i> , 1995, 88, 525-531.   | 4.3 | 8         |
| 120 | Definition and Diagnosis of Acute Kidney Injury in Cirrhosis. <i>Digestive Diseases</i> , 2015, 33, 539-547.   | 1.9 | 7         |
| 121 | Utility of shear-wave elastography to differentiate low from advanced degrees of liver fibrosis in patients with hepatitis C virus infection of native and transplant livers. <i>Journal of Clinical Ultrasound</i> , 2018, 46, 311-318. | 0.8 | 7         |
| 122 | Insurance Status But Not Race and Ethnicity Are Associated With Outcomes in a Large Hospitalized Cohort of Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 565-572.e5.                              | 4.4 | 7         |
| 123 | Latest Treatment of Acute Kidney Injury in Cirrhosis. <i>Current Treatment Options in Gastroenterology</i> , 2020, 18, 281-294.  | 0.8 | 7         |
| 124 | Admission Serum Metabolites and Thyroxine Predict Advanced Hepatic Encephalopathy in a Multicenter Inpatient Cirrhosis Cohort. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 1031-1040.e3.                                 | 4.4 | 7         |
| 125 | Effects of ursodeoxycholic acid on systemic, renal and forearm haemodynamics and sodium homeostasis in cirrhotic patients with refractory ascites. <i>Clinical Science</i> , 1999, 96, 467-474.  | 4.3 | 6         |
| 126 | Hepatorenal Syndrome: Do the Vasoconstrictors Work?. <i>Gastroenterology Clinics of North America</i> , 2011, 40, 581-598.   | 2.2 | 6         |



| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 127 | The impact of acute kidney injury in cirrhosis: does definition matter?. Gut, 2013, 62, 1091.2-1092.  | 12.1 | 6         |
| 128 | Impact of Bacterial Translocation on Sarcopenia in Patients with Decompensated Cirrhosis. Nutrients, 2019, 11, 2379.  | 4.1  | 5         |
| 129 | Letter to the Editor: Defining Acute on Chronic Liver Failure: More Elusive Than Ever. Hepatology, 2019, 70, 450-451.   | 7.3  | 5         |
| 130 | Feasibility and Procedural Safety of alfapump System Implantation by IR: Experience from the MOSAIC Study, a Multicenter, Open-Label Prospective Study in Cirrhotic Patients with Refractory Ascites. Journal of Vascular and Interventional Radiology, 2020, 31, 1256-1262.e3. | 0.5  | 5         |
| 131 | Efficacy and safety of glecaprevir/pibrentasvir in patients with HCV genotype 5/6: An integrated analysis of phase 2/3 studies. Liver International, 2020, 40, 2385-2393.   | 3.9  | 5         |
| 132 | Systemic hemodynamic, forearm vascular, renal, and humoral responses to sustained cardiopulmonary baroreceptor deactivation in well-compensated cirrhosis*1. Hepatology, 1995, 21, 717-724.   | 7.3  | 4         |
| 133 | Does Losartan Work After All?. American Journal of Gastroenterology, 2003, 98, 1222-1224.   | 0.4  | 4         |
| 134 | The effect of single oral low-dose losartan on posture-related sodium handling in post-TIPS ascites-free cirrhosis. Hepatology, 2006, 44, 640-649.  | 7.3  | 4         |
| 135 | Treatment to Improve Acute Kidney Injury in Cirrhosis. Current Treatment Options in Gastroenterology, 2015, 13, 235-248.  | 0.8  | 4         |
| 136 | Renal dysfunction in cirrhosis: diagnosis, treatment and prevention. MedGenMed: Medscape General Medicine, 2004, 6, 9.  | 0.2  | 4         |
| 137 | Excess nitric oxide in preascites: another piece in the puzzle. American Journal of Gastroenterology, 2002, 97, 2167-2169.  | 0.4  | 3         |
| 138 | SAT-141-The diagnosis of hepatorenal syndrome: How much does use of the 2015 revised consensus recommendations affect earlier treatment and serum creatinine at treatment start?. Journal of Hepatology, 2019, 70, e692-e693.   | 3.7  | 3         |
| 139 | Portal hypertensive gastropathy. Gastroenterology and Hepatology, 2007, 3, 428-73.  | 0.1  | 3         |
| 140 | Acute renal dysfunction in liver cirrhosis. Gastroenterology and Hepatology, 2013, 9, 830-2.  | 0.1  | 2         |
| 141 | Prognosis of hospitalized patients with cirrhosis and acute kidney disease. Liver International, 2022, , .  | 3.9  | 2         |
| 142 | Acute-on-Chronic Liver Failure. American Journal of Gastroenterology, 2022, 117, 831-834.   | 0.4  | 2         |
| 143 | The Role of Liver Biopsy in the Management of Patients with Liver Disease. Canadian Journal of Gastroenterology & Hepatology, 2003, 17, 651-654.  | 1.7  | 1         |
| 144 | Renal Failure in Cirrhosis. , 2018, , 262-280.e5.   |      | 1         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 145 | SAT-139-Predictive factors for the development of acute-on-chronic liver failure in a North American cohort of hospitalized patients with cirrhosis and decompensation. <i>Journal of Hepatology</i> , 2019, 70, e691-e692. | 3.7 | 1         |
| 146 | Reply to: Correspondence on "Clinical features and evolution of bacterial infection-related acute-on-chronic liver failure". <i>Journal of Hepatology</i> , 2021, 75, 1010-1012.  | 3.7 | 1         |
| 147 | Refractory ascites in cirrhosis: Roles of volume expansion and plasma atrial natriuretic factor level elevation. <i>Hepatology</i> , 1993, 18, 519-528.   | 7.3 | 1         |
| 148 | Un-precipitated acute kidney injury is uncommon among stable patients with cirrhosis and ascites. , 2018, 38, 1785.   |     | 1         |
| 149 | Management of Ascites. , 2005, , 301-317.   |     | 1         |
| 150 | Hepatorenal Syndrome: Are We Doing Better?. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2004, 18, 121-122.   | 1.7 | 0         |
| 151 | Vaptans for Ascites " Chances and Risks. <i>Frontiers of Gastrointestinal Research</i> , 2010, , 91-101.  | 0.1 | 0         |
| 152 | Speckle tracking echocardiography in cirrhosis: is it ready for prime time?. <i>Hepatology International</i> , 2014, 8, 10-13.  | 4.2 | 0         |
| 153 | EASL Recognition Awardee for 2014: Prof. Tilman Sauerbruch. <i>Journal of Hepatology</i> , 2014, 61, 469-471.   | 3.7 | 0         |
| 154 | Cardiac changes in pediatric liver transplant recipients: are they truly irreversible?. <i>Hepatology International</i> , 2016, 10, 390-393.  | 4.2 | 0         |
| 155 | IDDF2018-ABS-0067" Efficacy and safety of glecaprevir/pibrentasvir in patients with hcv genotype 5 or 6 infection: the endurance-5, 6 study. , 2018, , .  |     | 0         |
| 156 | Reply. <i>Liver Transplantation</i> , 2019, 25, 1586-1587.  | 2.4 | 0         |
| 157 | Reply. <i>Liver Transplantation</i> , 2020, 26, 1541-1542.  | 2.4 | 0         |
| 158 | REPLY:. <i>Hepatology</i> , 2021, 74, 2916-2917.  | 7.3 | 0         |
| 159 | Management of Ascites. , 2020, , 11-30.   |     | 0         |
| 160 | Historical Aspects of Ascites and the Hepatorenal Syndrome. <i>Clinical Liver Disease</i> , 2021, 18, 14-27.  | 2.1 | 0         |
| 161 | Cirrhosis; Acute Kidney Injury. , 2020, , 514-525.  |     | 0         |